Dr. Danyi Wen (President & CEO of LIDE) introduced LIDE Biotech's translational medicine service platform and business strategy. She also introduced translational applications of OncoVee® MiniPDX on both personalized oncology and the oncology drug screening. As an in vivo version of the organoid assay, OncoVee® MiniPDX is a 7-day in vivo oncology drug efficacy test.
Professor Hans Clevers is an international pioneer in the research field of "Organoid". He is very impressed by LIDE’s innovated application of organoid assay. In his review articles, Professor Clevers foresaw some potential applications of three major functional diagnosis assays: Conditional Reprogrammed Cells, Organoid and PDX. Professor Clevers was happy to see that LIDE put his prediction into real practice. Hans also provided valuable suggestions on how to use CRISPR for target validation with CR cell lines and organoid.
Roche China team and Professor Hans Clevers also had an in-depth discussion on the potential collaboration with LIDE in new drug R&D. Professor Hans Clevers, Dr. Hong Shen and Roche China team also visited LIDE’s laboratory and AAALAC accredited animal facility. They were impressed by working scenario that a group of scientists and technicians did excellent work in the lab of LIDE. We wish Professor Hans, Roche China and LIDE a fruitful collaboration in the near future!